FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock

European Journal of Pharmacology

Volumn 327, Issue 2-3, 1997, Pages 169-174

  Yamamoto, Nobuchika ^a   Sakai, Fumihiko ^a   Yamazaki, Harumi ^a   Sato, Natsuki ^a   Nakahara, Kunio ^a   Okuhara, Masakuni ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Interleukin 1; Septic shock; TNF (tumor necrosis factor )

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ANTIINFLAMMATORY AGENT; ENDOTOXIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY INJURY; LETHALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; SEPTIC SHOCK;

EID: 0030961386     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)89657-4     Document Type: Article

References (26)

1. Alexander H.R., Doherty G.M., Gurresch C.M., Venzon D.J., Norton J.A. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 173:1991;1029-1032.
2. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
3. Calandra T., Baumgartner J.D., Grau G.E., Wu M.M., Lambert P.H., Schellekens J., Verhoef J., Glauser M.P. Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J. Infect. Dis. 161:1990;982-987.
4. Cannon J.G., Tompkins R.G., Gelfand J.A., Michie H.R., Stanford G.G., Van der Meer J.W., Endres S., Lonnemann G., Corsetti J., Chernow B., Wilmore D.W., Wolff S.M., Dinarello C.A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161:1990;79-84.
5. Carrico C.J., Meakins J.L., Marshall J.C., Fry D., Maier R.V. Multiple-organ-failure syndrome. Arch. Surg. 121:1986;196-208.
6. Cobb J.P., Danner R.L. Nitric oxide and septic shock. J. Am. Med. Assoc. 275:1996;1192-1196.
7. Dinarello C.A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 163:1991;1177-1184.
8. Dinarello C.A., Wolff S.M. The role of interleukin-1 in disease. New Engl. J. Med. 328:1993;106-113.
9. Endres S., Cannon J.G., Ghorbani R., Dempsey R.A., Sisson S.D., Lonnemann G., Van der Meer J.W., Wolff S.M., Dinarello C.A. In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur. J. Immunol. 19:1989;2327-2333.
10. Fisher C.J. Jr., Opal S.M., Dhainaut J.F., Stephens S., Zimmerman J.L., Nightingale P., Harris S.J., Schein R.M., Panacek E.A., Vincent J.L., Foulke G.E., Warren E.L., Garrard C., Park G., Bodmer M.W., Cohen J., Van der Linden C., Cross A.S., Sadoff J.C. T.C.S.S.S. Group: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21:1993;318-327.
11. Fisher C.J. Jr., Dhainaut J.F., Opal S.M., Pribble J.P., Balk R.A., Slotman G.J., Iberti T.J., Rackow E.C., Shapiro M.J., Greenman R.L., Reines H.D., Shelly M.P., Thompson B.W., LaBrecque J.F., Catalano M.A., Knaus W.A., Sadoff J.C. Phase III rhIL-1ra Sepsis Syndrome Study Group: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. J. Am. Med. Assoc. 271:1994;1836-1843.
12. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., Marey A., Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest. 101:1992;816-823.
13. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C.J., Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J. Infect. Dis. 172:1995;296-301.
14. Girardin E., Grau G.E., Dayer J.M., Roux-Lombard P., Lambert P.H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New Engl. J. Med. 319:1988;397-400.
15. Hesse D.G., Tracey K.J., Fong Y., Manogue K.R., Palladino M.A. Jr., Cerami A., Shires G.T., Lowry S.F. Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 166:1988;147-153.
16. Laubach V.E., Shesely E.G., Smithies O., Sherman P.A. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA. 92:1995;10688-10692.
17. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., Stevens K., Xie Q.W., Sokol K., Hutchinson N. Altered responses to bacterial infection and endotoxin shock in mice lacking inducible nitric oxide synthase. Cell. 81:1995;641-650.
18. McCloskey R.V., Straube R.C., Sanders C., Smith S.M., Smith C.R. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 121:1994;1-5.
19. Natanson C., Hoffman W.D., Suffredini A.F., Eichacker P.Q., Danner R.L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Int. Med. 120:1994;771-783.
20. Nathan C., Sporn M. Cytokines in context. J. Cell Biol. 113:1991;981-986.
21. Ohlsson K., Bjork P., Bergenfeldt M., Hageman R., Thompson R.C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 348:1990;550-552.
22. Okusawa S., Gelfand J.A., Ikejima T., Connolly R.J., Dinarello C.A. Interleukin 1 induces a shock-like state in rabbits. J. Clin. Invest. 81:1988;1162.
23. Russell D.A., Tucker K.K., Chinookoswong N., Thompson R.C., Kohno T. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function. J. Infect. Dis. 171:1995;1528-1538.
24. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
25. Wakabayashi G., Gelfand J.A., Burke J.F., Thompson R.C., Dinarello C.A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5:1991;338-343.
26. Yamamoto N., Sakai F., Ymazaki H., Nakahara K., Okuhara M. Effect of FR167653, a cytokine suppressive agent, on LPS-induced disseminated intravascular coagulation in rats. Eur. J. Pharmacol. 314:1996;137-142.